Patents by Inventor Karen Vanhoorelbeke

Karen Vanhoorelbeke has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Patent number: 11427649
    Abstract: The present invention relates to methods of treatment by human ADAMTS13 inhibition in circulatory assist device induced haemorrhagic complication such as a bleeding disorder, in particular, bleeding after left ventricular assist device (LVAD) implantation. The present invention further relates to specific monoclonal antibodies inhibiting ADAMTS13 function.
    Type: Grant
    Filed: October 1, 2020
    Date of Patent: August 30, 2022
    Assignee: KATHOLIEKE UNIVERSITEIT LEUVEN
    Inventors: Karen Vanhoorelbeke, Shannen Deconinck, Hendrik Feys, An-Sofie Schelpe
  • Patent number: 11339226
    Abstract: The present invention further relates to specific humanised monoclonal antibodies inhibiting ADAMTS13 function. The present invention relates to methods of treatment by human ADAMTS13 inhibition in circulatory assist device induced haemorrhagic complication such as a bleeding disorder, in particular, bleeding after left ventricular assist device (LVAD) implantation.
    Type: Grant
    Filed: June 13, 2018
    Date of Patent: May 24, 2022
    Assignee: Katholieke Universiteit Leuven
    Inventors: Karen Vanhoorelbeke, Shannen F. Deconinck, An-Sofie Schelpe
  • Publication number: 20210402403
    Abstract: In general the present invention concerns 1) single cell trapping of a viable cell in separate well from a plurality of wells in an array of wells, 2) single cell analysis for the selected cell and 3) single cell lifting of the yet viable cell from the well by an optical tweezer. Furthermore resent invention concerns a cell trap and lift device for B lymphocytes, the device comprising an array of wells in in polymer matrix comprising an off-stoichiometry thiol-ene polymer of the group consisting of off-stoichiometry thiol-ene (OSTE) and off-stoichiometry thiol-ene-epoxy (OSTE+) or a combination thereof that have been grafted with methacrylated polyethylene glycol (methoxy polyethylene glycol methacrylate or (M-PEG-M)) of a number average molecular weight of Mn 2000.
    Type: Application
    Filed: November 8, 2019
    Publication date: December 30, 2021
    Inventors: Jeroen Lammertyn, Karen VanHoorelbeke, Nick Geukens, Sara Horta, Jolien Breukers
  • Publication number: 20210017292
    Abstract: The present invention relates to methods of treatment by human ADAMTS13 inhibition in circulatory assist device induced haemorrhagic complication such as a bleeding disorder, in particular, bleeding after left ventricular assist device (LVAD) implantation. The present invention further relates to specific monoclonal antibodies inhibiting ADAMTS13 function.
    Type: Application
    Filed: October 1, 2020
    Publication date: January 21, 2021
    Inventors: Karen VANHOORELBEKE, Shannen DECONINCK, Hendrik FEYS, An-Sofie SCHELPE
  • Patent number: 10829562
    Abstract: The present invention relates to methods of treatment by human ADAMTS13 inhibition in circulatory assist device induced haemorrhagic complication such as a bleeding disorder, in particular, bleeding after left ventricular assist device implantation. The present invention further relates to specific monoclonal antibodies inhibiting ADAMTS13 function.
    Type: Grant
    Filed: December 8, 2016
    Date of Patent: November 10, 2020
    Assignee: KATHOLIEKE UNIVERSITEIT LEUVEN
    Inventors: Karen Vanhoorelbeke, Shannen Deconinck, Hendrik Feys, An-Sofie Schelpe
  • Publication number: 20200308303
    Abstract: The present invention further relates to specific humanised monoclonal antibodies inhibiting ADAMTS13 function. The present invention relates to methods of treatment by human ADAMTS13 inhibition in circulatory assist device induced haemorrhagic complication such as a bleeding disorder, in particular, bleeding after left ventricular assist device (LVAD) implantation.
    Type: Application
    Filed: June 13, 2018
    Publication date: October 1, 2020
    Inventors: Karen Vanhoorelbeke, Shannen F. Deconinck, An-Sofie Schelpe
  • Publication number: 20180362665
    Abstract: The present invention relates to methods of treatment by human ADAMTS13 inhibition in circulatory assist device induced haemorrhagic complication such as a bleeding disorder, in particular, bleeding after left ventricular assist device implantation. The present invention further relates to specific monoclonal antibodies inhibiting ADAMTS13 function.
    Type: Application
    Filed: December 8, 2016
    Publication date: December 20, 2018
    Inventors: Karen VANHOORELBEKE, Shannen DECONINCK, Hendrik FEYS, An-Sofie SCHELPE
  • Patent number: 7754215
    Abstract: The present invention clearly demonstrates that vWF-collagen interaction, via the A3 domain of vWF, plays an important role in acute platelet-dependent arterial thrombus formation and that blocking the A3 domain in a vWF-collagen interaction can induce complete abolition of thrombus formation in the injured and stenosed baboon femoral arteries. Accordingly, an antibody or an antigen recognizing fragment thereof binding specifically to the A3 domain of vWF or an epitope thereof can be used for the prevention of acute arterial thrombotic syndromes or to manufacture medicines to for the prevention of acute arterial thrombotic syndromes.
    Type: Grant
    Filed: December 18, 2006
    Date of Patent: July 13, 2010
    Assignee: K.U. Leuven Research & Development
    Inventors: Hans Deckmyn, Nancy Cauwenberghs, Karen Vanhoorelbeke
  • Publication number: 20100099202
    Abstract: The present invention relates to a method for detecting von-Willebrand factor (vWF) activity comprising assaying a sample in the presence of a soluble form or portion of glycoprotein Ib(?) (GPIb(?)) and ristocetin, or a functionally equivalent substance. Additionally, the invention relates to the use of the aforementioned soluble form or portion of glycoprotein Ib(?), of ristocetin or a functional equivalent substance, of specifically reacting anti-GPIB(?) antibody(ies) and/or of specific binding partners, like specifically reacting anti-vWF antibody(ies) for carrying out the method of the invention. Furthermore, the present invention relates to kits for carrying out the method of the invention.
    Type: Application
    Filed: November 17, 2009
    Publication date: April 22, 2010
    Inventors: Nancy Cauwenberghs, Karen Vanhoorelbeke, Hans Deckmyn
  • Patent number: 7622259
    Abstract: The present invention relates to a method for detecting von-Willebrand factor (vWF) activity comprising assaying a sample in the presence of a soluble form or portion of glycoprotein Ib(?) (GPIb(?) and ristocetin, or a functionally equivalent substance. Additionally, the invention relates to the use of the aforementioned soluble form or portion of glycoprotein Ib(?), of ristocetin or a functional equivalent substance, of specifically reacting anti-GPIB(?) antibody(ies) and/or of specific binding partners, like specifically reacting anti-vWF antibody(ies) for carrying out the method of the invention. Furthermore, the present invention relates to kits for carrying out the method of the invention.
    Type: Grant
    Filed: July 5, 2000
    Date of Patent: November 24, 2009
    Assignee: K.U. Leuven Research & Development
    Inventors: Nancy Cauwenberghs, Karen Vanhoorelbeke, Hans Deckmyn
  • Publication number: 20070081999
    Abstract: The present invention clearly demonstrates that vWF-collagen interaction plays an important role in acute platelet-dependent arterial thrombus formation and that blockade of vWF-collagen interaction can induce complete abolition of thrombus formation in the injured and stenosed baboon femoral arteries. Accordingly, a blocker of vWF-collagen can be used as a compound for the prevention of acute arterial thrombotic syndromes or to manufacture medicines to prevention of acute arterial thrombotic syndromes.
    Type: Application
    Filed: December 18, 2006
    Publication date: April 12, 2007
    Inventors: Hans DECKMYN, Nancy Cauwenberghs, Karen Vanhoorelbeke
  • Publication number: 20040071704
    Abstract: The present invention clearly demonstrates that vWF-collagen interaction plays an important role in acute platelet-dependent arterial thrombus formation and that blockade of vWF-collagen interaction can induce complete abolition of thrombus formation in the injured and stenosed baboon femoral arteries. Accordingly, a blocker of vWF-collagen can be used as a compound for the prevention of acute arterial thrombotic syndromes or to manufacture medicines to prevention of acute arterial thrombotic syndromes.
    Type: Application
    Filed: November 21, 2003
    Publication date: April 15, 2004
    Inventors: Hans Deckmyn, Nancy Cauwenberghs, Karen Vanhoorelbeke